CERo Therapeutics Holdings, Inc. Common Stock (CERO)

CERo Therapeutics Holdings, Inc. Common Stock (CERO) is a Biotechnology company in the Healthcare sector listed on the NASDAQ.

As of Oct 23, 2026: market cap $644,678; returns 1 day -2.0%, 1 year -99.8%.

CERo Therapeutics Holdings Inc. (OTCQB: CERO) is a clinical-stage biotechnology company focused on the development of novel therapeutic candidates for cancer. Its primary asset is CER-1236, an investigational therapy currently in Phase 1 clinical trials for the treatment of Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS).

Groups CERO belongs to

• Biotechnology
• Clinical Stage
• Clinical Stage Biotech
• Healthcare
• Oncology
• Cancer Therapeutics
• Immunotherapy
• Hematologic Malignancies
• Biopharmaceutical
• Life Sciences

CERO financial model: income statement, cash flow and balance sheet